Effects of Acetyl-L-Carnitine on Tuberculosis Patients
Author Information
Author(s): Emilio Jirillo, Maria Altamura, Carlo Marcuccio, Cosimo Tortorella, Claudio De Simone, Salvatore Antonaci
Primary Institution: Medical School, University of Bari, Bari, Italy
Hypothesis
Can acetyl-L-carnitine improve immune response in patients with active pulmonary tuberculosis?
Conclusion
Acetyl-L-carnitine improved antibacterial activity in tuberculosis patients after 30 days of treatment.
Supporting Evidence
- Acetyl-L-carnitine was administered orally at a dose of 2 g/day for 30 days.
- Antibacterial activity increased in patients treated with acetyl-L-carnitine.
- Serum levels of TNF-alpha did not change significantly between the two groups.
Takeaway
This study tested a medicine called acetyl-L-carnitine to see if it helps people with tuberculosis fight the disease better.
Methodology
A double-blind, randomized, controlled trial with 20 patients receiving either acetyl-L-carnitine or placebo for 30 days.
Limitations
The study had a small sample size and focused only on short-term effects.
Participant Demographics
20 individuals with active pulmonary tuberculosis, including both acute and chronic cases.
Want to read the original?
Access the complete publication on the publisher's website